Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol

• Herman Goossens,
• Ann Van den Bruel,
• Jan Y Verbakel,
• Beatrice Scholtes,
• An De Sutter,
• Laetitia Buret,
• Pierre Van Damme,
• Samuel Coenen,
• Robin Bruyndonckx,
• Els Duysburgh,
• Stefan Heytens,
• Niels Adriaenssens,
• Isabelle Desombere

Affiliations

Herman Goossens

Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerpen, Belgium

Ann Van den Bruel

Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium

Jan Y Verbakel

Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium

Beatrice Scholtes

Département des Sciences Cliniques, University of Liege, Liege, Belgium

An De Sutter

Department of Public Health and Primary Care, Ghent University, Gent, Belgium

Laetitia Buret

Département des Sciences Cliniques, University of Liege, Liege, Belgium

Pierre Van Damme

Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerpen, Belgium

Samuel Coenen

Department of Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerpen, Belgium

Robin Bruyndonckx

Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), Data Science Institute, Hasselt University, Hasselt, Belgium

Els Duysburgh

Department of Epidemiology and Public Health, Sciensano, Brussel, Belgium

Stefan Heytens

Department of Public Health and Primary Care, Ghent University, Gent, Belgium

Niels Adriaenssens

Department of Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerpen, Belgium

Isabelle Desombere

Department of Infectious Diseases in Humans, Sciensano, Brussel, Belgium